These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22514654)

  • 1. Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors.
    Karman J; Gumlaw NK; Zhang J; Jiang JL; Cheng SH; Zhu Y
    PLoS One; 2012; 7(4):e34684. PubMed ID: 22514654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
    Monahan PE; Lothrop CD; Sun J; Hirsch ML; Kafri T; Kantor B; Sarkar R; Tillson DM; Elia JR; Samulski RJ
    Mol Ther; 2010 Nov; 18(11):1907-16. PubMed ID: 20700109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
    Finn JD; Hui D; Downey HD; Dunn D; Pien GC; Mingozzi F; Zhou S; High KA
    Mol Ther; 2010 Jan; 18(1):135-42. PubMed ID: 19904235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing transduction of the liver by adeno-associated viral vectors.
    Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM
    Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
    Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
    J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice.
    Manning ML; Mason-Osann E; Onda M; Pastan I
    J Immunol; 2015 Feb; 194(4):1695-701. PubMed ID: 25560410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.
    Scallan CD; Jiang H; Liu T; Patarroyo-White S; Sommer JM; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Mar; 107(5):1810-7. PubMed ID: 16249376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement is an essential component of the immune response to adeno-associated virus vectors.
    Zaiss AK; Cotter MJ; White LR; Clark SA; Wong NC; Holers VM; Bartlett JS; Muruve DA
    J Virol; 2008 Mar; 82(6):2727-40. PubMed ID: 18199646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.
    Xin KQ; Mizukami H; Urabe M; Toda Y; Shinoda K; Yoshida A; Oomura K; Kojima Y; Ichino M; Klinman D; Ozawa K; Okuda K
    J Virol; 2006 Dec; 80(24):11899-910. PubMed ID: 17005662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy.
    Hareendran S; Ramakrishna B; Jayandharan GR
    Eur J Immunol; 2016 Jan; 46(1):154-66. PubMed ID: 26443873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.
    Meliani A; Boisgerault F; Hardet R; Marmier S; Collaud F; Ronzitti G; Leborgne C; Costa Verdera H; Simon Sola M; Charles S; Vignaud A; van Wittenberghe L; Manni G; Christophe O; Fallarino F; Roy C; Michaud A; Ilyinskii P; Kishimoto TK; Mingozzi F
    Nat Commun; 2018 Oct; 9(1):4098. PubMed ID: 30291246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
    Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
    Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver.
    Murphy SL; Li H; Zhou S; Schlachterman A; High KA
    Mol Ther; 2008 Jan; 16(1):138-45. PubMed ID: 17955024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity.
    Zhang YC; Powers M; Wasserfall C; Brusko T; Song S; Flotte T; Snyder RO; Potter M; Scott-Jorgensen M; Campbell-Thompson M; Crawford JM; Nick HS; Agarwal A; Ellis TM; Atkinson MA
    Gene Ther; 2004 Feb; 11(3):233-40. PubMed ID: 14737082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
    Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
    Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.
    Aldrich WA; Ren C; White AF; Zhou SZ; Kumar S; Jenkins CB; Shaw DR; Strong TV; Triozzi PL; Ponnazhagan S
    Gene Ther; 2006 Jan; 13(1):29-39. PubMed ID: 16136165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
    Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
    Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to circumvent humoral immunity to adeno-associated viral vectors.
    Tse LV; Moller-Tank S; Asokan A
    Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.